Skip to content

For the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adult patients

COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis. In clinical trials in patients with moderate to severe plaque psoriasis, a higher rate of infections was observed in subjects treated with COSENTYX compared to placebo-treated subjects. A similar increase in risk of infection was seen in placebo-controlled trials in patients with psoriatic arthritis and ankylosing spondylitis. Do not administer COSENTYX to patients with active TB infection. The two new indications follow the earlier FDA approval for Cosentyx in January 2015 to treat adult patients with moderate-to-severe plaque psoriasis, and European approval for AS and PsA in November 2015. Otezla is a prescription medicine approved for the treatment of adult patients with active psoriatic arthritis. Otezla is also approved for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.

Other side effects include diabetes, psoriasis, irritable bowel syndrome and more 2Learn more about moderate to severe plaque psoriasis and find answers to common questions at Enbrel. ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with psoriatic arthritis. Learn more about psoriatic arthritis and find answers to common questions at Enbrel. About 1 million adult Americans have it. Your doctor should test you for TB before you take ENBREL and monitor you closely for TB before, during, and after ENBREL treatment, even if you have tested negative for TB. ENBREL is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Food and Drug Administration for the Treatment of Patients with Moderate to Severe Plaque Psoriasis. (FDA) for the treatment of adults with active psoriatic arthritis. A New Drug Submission (NDS) for psoriatic arthritis was submitted to health authorities in Canada in the second quarter of 2013.

In a clinical study of adult patients with active psoriatic arthritis using HUMIRA:. If there is active disease, TB treatment must be begun before initiation of the biologic. Both studies evaluated the efficacy and safety of Humira in clearing skin in moderate to severe adult plaque psoriasis patients versus placebo. Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential. In September 2009, the US Food and Drug Administration (FDA) approved its use for adult patients with moderate-to-severe plaque psoriasis. A total of 146 patients with active PsA, defined as having three or more tender joints, three or more swollen joints, and either an elevated C-reactive protein (CRP) or morning stiffness lasting 45 minutes or more were recruited from dermatological practices.

What Is Plaque Psoriasis?

Other side effects include diabetes, psoriasis, irritable bowel syndrome and more 3Psoriasis Online Medical Reference – from diagnosis through treatment. Psoriasis patients are not only more likely to have CV risk factors but severe psoriasis may serve as an independent risk factor for CV mortality. PsA, ankylosing spondylitis, and chronic to severe plaque psoriasis in adults. Find information to help you understand psoriatic arthritis at Enbrel.com. This section also tells you about joint pain and permanent joint damage, and explains why you should talk to your doctor and find an appropriate treatment to relieve your joint and skin symptoms and help limit joint damage. ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with moderately to severely active rheumatoid arthritis. An assessment of any patient with psoriasis should include disease severity, the impact of disease on physical, psychological and social well-being, whether they have psoriatic arthritis, and the presence of any comorbidities. Discuss treatment options (including no active treatment), likely benefit from treatment, and side-effects; agree a management plan. If moderate-potency topical corticosteroids are ineffective in facial and flexural psoriasis then vitamin D analogues or tacrolimus ointment are recommended for intermittent use. Learn about REMICADE, active psoriatic arthritis treatment. It is often prescribed for moderate to severe plaque psoriasis, erythrodermic psoriasis (a medical emergency, where psoriasis completely covers the entirety of the skin), and some cases of pustular psoriasis. Learn more about the treatment of plaque psoriasis. STELARA is a prescription medicine approved to treat adults 18 years and older with moderate or severe plaque psoriasis that involves large areas or many areas of their body, who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills). LEARN MORE STELARA is a prescription medicine approved to treat adults 18 years and older with active psoriatic arthritis, either alone or with methotrexate. The information on this site is intended for the use of patients and caregivers in the United States and Puerto Rico only.

Psoriatic Arthritis Treatment

For the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA). Active psoriatic arthritis impacts more than just the joint.